EGFR and non-small cell lung carcinoma: These proteins are also associated with disease progression and poor prognosis, making them promising targets for cancer therapeutics designed to treat many types of solid cancers, including lung cancer.10,11 In this study, we found that a novel IAP inhibitor, HM90822B, originally designed to target IAP family and EGFR and screened as an IAP inhibitor, greatly sensitized several NSCLC cells to apoptosis and cell growth arrest.